ArticleCells2026
Autism Spectrum Disorder: High-Resolution Elucidation of Mitochondrial Dysregulation in Larval Zebrafish Gut.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although gastrointestinal distress is both common and debilitating in individuals with autism spectrum disorder (ASD), underpinning mechanisms-and therefore effective management strategies-are not fully elucidated. The current study employed well-established valproic acid ASD model in larval zebrafish to more comprehensively characterize mitochondrial dysregulation. Whole body redox status and mitochondrial respiration, as well as protein expression in the mitophagy-lysosomal axis in the mid-intestine was assessed. In addition, high-resolution microscopy of the gut was used to assess mitochondrial morphometrics and distribution. Redox imbalance was evident from increased oxygen radical levels and decreased endogenous antioxidant capacity, as well as depression of whole body mitochondrial respiration. Upregulation of endo-lysosomal pathway markers (Rab5, LAMP1) together with reduced expression in mitophagy and autophagy markers (PINK1, LC3B) suggests a potential impairment of canonical mitophagy in the ASD-like gut. High-resolution imaging further revealed smaller, more circular mitochondria, indicative of a morphological fission bias. Abnormal mitochondrial distribution patterns were also evident. Together, current data points to primary mitochondrial dysfunction as a potential feature of the ASD-like gut. Furthermore, data suggest potential insufficiencies in mitochondrial recycling as potential role player in ASD-associated (gut) mitochondrial pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.